End-of-day quote
Shanghai S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
36.3
CNY
|
+3.04%
|
|
+7.08%
|
-21.87%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,423
|
12,508
|
16,740
|
25,873
|
20,215
|
-
|
-
|
Enterprise Value (EV)
1 |
7,423
|
12,508
|
16,740
|
25,873
|
20,215
|
20,215
|
20,215
|
P/E ratio
|
111
x
|
-23.9
x
|
47.7
x
|
31.4
x
|
18.7
x
|
14.1
x
|
12.5
x
|
Yield
|
-
|
-
|
-
|
0.65%
|
0.91%
|
1.57%
|
-
|
Capitalization / Revenue
|
-
|
1.03
x
|
1.19
x
|
1.66
x
|
1.13
x
|
0.92
x
|
0.9
x
|
EV / Revenue
|
-
|
1.03
x
|
1.19
x
|
1.66
x
|
1.13
x
|
0.92
x
|
0.9
x
|
EV / EBITDA
|
-
|
-63
x
|
19.2
x
|
18.7
x
|
11.4
x
|
8.9
x
|
8.58
x
|
EV / FCF
|
-
|
-
|
-
|
-3,066,036,071
x
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-0%
|
-
|
-
|
-
|
Price to Book
|
-
|
4.59
x
|
5.46
x
|
7.14
x
|
4.37
x
|
3.28
x
|
2.77
x
|
Nbr of stocks (in thousands)
|
556,891
|
556,891
|
556,891
|
556,891
|
556,891
|
-
|
-
|
Reference price
2 |
13.33
|
22.46
|
30.06
|
46.46
|
36.30
|
36.30
|
36.30
|
Announcement Date
|
4/23/21
|
3/30/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
12,149
|
14,051
|
15,623
|
17,824
|
21,907
|
22,528
|
EBITDA
1 |
-
|
-198.5
|
871.5
|
1,382
|
1,767
|
2,273
|
2,355
|
EBIT
1 |
-
|
-497.4
|
430
|
1,023
|
1,361
|
1,850
|
2,046
|
Operating Margin
|
-
|
-4.09%
|
3.06%
|
6.55%
|
7.63%
|
8.44%
|
9.08%
|
Earnings before Tax (EBT)
1 |
-
|
-494.1
|
442.8
|
1,027
|
1,366
|
1,857
|
2,051
|
Net income
1 |
66.07
|
-523.2
|
349.7
|
822.1
|
1,082
|
1,434
|
1,619
|
Net margin
|
-
|
-4.31%
|
2.49%
|
5.26%
|
6.07%
|
6.54%
|
7.19%
|
EPS
2 |
0.1200
|
-0.9395
|
0.6300
|
1.480
|
1.942
|
2.573
|
2.906
|
Free Cash Flow
|
-
|
-
|
-
|
-8.439
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-0.05%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
0.3000
|
0.3300
|
0.5700
|
-
|
Announcement Date
|
4/23/21
|
3/30/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-8.44
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-17.5%
|
12.1%
|
23.8%
|
23.5%
|
23.5%
|
22.2%
|
ROA (Net income/ Total Assets)
|
-
|
-3.78%
|
2.51%
|
-
|
6.73%
|
7.08%
|
7.53%
|
Assets
1 |
-
|
13,828
|
13,938
|
-
|
16,084
|
20,263
|
21,489
|
Book Value Per Share
2 |
-
|
4.900
|
5.500
|
6.500
|
8.300
|
11.10
|
13.10
|
Cash Flow per Share
2 |
-
|
1.000
|
3.230
|
1.210
|
2.490
|
3.470
|
3.890
|
Capex
1 |
-
|
220
|
432
|
680
|
652
|
1,945
|
549
|
Capex / Sales
|
-
|
1.81%
|
3.07%
|
4.35%
|
3.66%
|
8.88%
|
2.44%
|
Announcement Date
|
4/23/21
|
3/30/22
|
3/30/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
36.3
CNY Average target price
52.83
CNY Spread / Average Target +45.54% Consensus |
1st Jan change
|
Capi.
|
---|
| -21.87% | 2.79B | | +30.08% | 699B | | +25.07% | 571B | | -4.57% | 364B | | +18.30% | 326B | | +2.94% | 286B | | +14.68% | 236B | | +4.71% | 198B | | -12.43% | 194B | | -4.03% | 154B |
Other Pharmaceuticals
|